INTRODUCTION
Acute pulmonary embolism (PE) is the third common cardiovascular causes of hospital admission and mortality, following stroke, and acute coronary syndrome. Predictors of mortality following acute PE include: Simultaneous malignancy, chronic pulmonary disease, age older than 70 years, systemic hypotension at time of admission, heart failure, right ventricular akynesia and dysfunction, and biomarkers such as B-type natriuretic peptide and cardiac troponins. [1] [2] [3] Among hospitalized patients, hyponatremia is a common electrolyte abnormality, and recent data showed that it had associated with poor outcome in patients with acute Study patients 252 consecutive patients with confi rmed diagnosis of PE admi ed our hospital were included in this study and prospectively followed. The fi nal outcome and prognosis were evaluated during the course of hospitalization and within 30 days of initial presentation.
Inclusion criteria
Evidence of PE should be documented by either computed assisted tomography pulmonary angiography or by ventilation/perfusion pulmonary scintigraphy besides clinical and investigational evidence in favor of the diagnosis in the absence of an alternative one.
Exclusion criteria
Patients who were not defi nitively diagnosed as having PE were excluded from this study.
Defi nition of hyponatremia and outcomes
The hyponatremia was defi ned in our study as a baseline serum sodium level 137 mmol/L or lower. Sodium level between 135 and 137 was considered mild hyponatremia and amounts of sodium bellow 135 had severe hyponatremia. [3] Our study outcome was pulmonary emboli related mortality within 30 days of initial presentation.
Clinical and demographic variables
At time of patients arrival in our hospital with suspicious to PE, a detailed medical history was obtained through a standardized questionnaire containing specifi c questions about symptoms, presence of known risk factors such as: Use of hormone replacement therapy, pregnancy or oral contraceptives, concomitant malignancy, recent trauma or surgery within the last 4 weeks, complete bed rest for >3 days, concurrent diseases, and medication use. In addition, variables such as hemoptysis prior to medication, altered menal status, New York Heart Association class, mode, and duration of predominant symptoms such as, chest pain, abdominal pain, fatigue, palpitations, dizziness, syncope, orthopnea, cough, and cyanosis at presentation and overt right ventricular failure prior the onset of symptoms and clinical signs included mean systolic blood pressure (SBP) and diastolic blood pressure, shock index (heart rate/SBP), hypoxemia, and evidence of deep venous thrombosis were considered. Severity of the PE was evaluated by PE severity index (PESI), a confi rmed prognostic model for patients with PE. [5] [6] [7] [8] We also used the simplifi ed PESI (sPESI) format, [9] which are included: History of malignancy, chronic cardiopulmonary disease, age >80 years, pulse >110 beats/min, SBP <100 mmHg, and SpO 2 <90%.
Statistical analyses
In order to compare baseline characteristics for patient discharges across three levels of serum sodium (<135, 135-137, and >137 mmol/L), we applied Kruskal-Wallis test for contiguous variables and Chi-square test for categorical variables. We used the log-rank test and survival analyses to compare the cumulative 1-month mortality by sodium level, and stratifi ed our evaluations of mortality by plasma sodium level and original PESI severity and its sPESI subclasses.
In order to evaluate the relation between plasma sodium level and mortality, we also used logistic regression analysis with adjusting for patient severity of illness by using all PESI severity models.
Ethics
The study method was approved by the Isfahan University Medical Ethics Review Commi ee, and all participants consciously signed a wri en consent. In this scheme, any intervention by the research team could not be applied and patients were treated under view of healthcare team and according to the protocol in the emergency department of the hospital.
RESULTS
Two hundred fi y-two patients with confi rmed diagnosis of PE (59% men, median age of 56 years, and mean age 59 years ranging from 19 to 95 years) were evaluated. We excluded 16 (6.5%) patients for missed next their followup, 6 (2.4%) patients refused to participate to this study, and 6 (2.4%) patients were died not correlated to PE or its side eff ect. The study cohort included 224 patient admi ed with a diagnosis of acute PE from Alzahra University Hospitals; 109 patients (48.7%) had normal sodium level (serum level >137 mmol/L). 115 patients had sodium level below 137 mmol/L. Of these, 56 (25%) had a sodium level 135-137 mmol/L, and 59 (26.3%) had a sodium level below 135 mmol/L. Primary patient characteristics by level of serum sodium are noted in Table 1. Association between plasma sodium level and 1 month mortality Overall, 53 of 224 patients (23.6%) died at the end of 30 days. As shown in Figure 1 , patients with a serum sodium level of >137, 135-137, and <135 mmol/L had a cumulative 1-month mortality of 14%, 21%, and 42% (P < 0.0001), respectively.
A er adjustment of patient for severity of PE by PESI risk class, mortality was also signifi cantly higher in patients with lower serum sodium level [ Table 2 ].
When the sPESI risk class was evaluated, the 30-day mortality remained signifi cantly increased for patients with sodium level lower than 135 mmol/L [Table 3, Figure 2 ]. In order to omi ed the role of some confounding variables such as history of cancer, heart failure, renal failure, or chronic obstructive pulmonary disease, all of them were excluded from analysis, but the mortality was still signifi cantly diff erent [ Figure 3 ]. 
DISCUSSION
According to our results, a signifi cant proportion of patients with PE (26.3%) is hyponatremic (serum sodium <135 mmol/L) at the time of presentation. Serum sodium <135 mmol/L was observed in only approximately 2% of the community subjects, but associated with a 3.5-fold increased incidence of adverse outcome. [5] Among the patients with PE and hyponatremia, had signifi cant higher 30-days mortality than patients without hyponatremia (42% for sodium level below 135 mmol/L vs. 14% for sodium level more than 137 mmol/L). So, severity of hyponatremia could increase mortality.
Our fi ndings show that the mortality of patients with high PESI score and low sodium level was about 3 times over normonatremic (serum sodium >137 mmol/L) group. So, it seems that we could be able to use sodium level as a prognostic factor in patients with PE. There are no another papers about using this factor in determination of mortality in these patients.
With exclusion of some confounding variables such as: Chronic lung disease, previous history of cancer, renal failure, or heart failure the results remained similar. So, hyponatremia adversely affects outcomes across the all subclasses in severity of illness (PESI risk classes I-V), even with exclusion of the lower-risk patients (low PESI score), the mortality was significantly increased. In addition, some studies show that mild hyponatremia in the general population associated with increased mortality. [6, 7] According to these it seems that hyponatremia is an independent predictor of short-term mortality in PE.
Hyponatremia can be an indicator of severity of disorders, which may be predictive of however not causally related to mortality. In the patients with cardiovascular disease, hyponatremia may suggestive of signifi cant physiologic abnormalities (e.g., low eff ective circulating volume with consequent disturbances of renal fi ltration rate and distal sodium delivery, raised levels of arginine vasopressin, or neurohormonal activation). [4] Hyponatremia is a signifi cant indicator of heart failure severity with poor prognosis. [5, 8, 9] Besides, in patients with cirrhosis and ascites while waiting for a liver transplant, hyponatremia is a great predictor of death. Adding hyponatremia to the model for end-stage liver disease (MELD) score is a be er predictor of death than the MELD score alone, especially in patients with low MELD scores. Interestingly, correction of hyponatremia in these patients may not improve prognosis a er liver transplantation.
In order to explain increased 1-month mortality among the PE patients with hyponatremia, we fi rst point to relation between hyponatremia and sympathetic nerves hyper activity. In patients with left ventricular dysfunction, hyponatremia is an indicator of neurohormonal activation. It might cause release of vasopressin leading to hyperactivity of the sympathetic and renin-angiotensin aldosterone system axis. [1] Neurohormonal activation was also seen in patients with pulmonary arterial hypertension and right ventricular dysfunction. [1, 10] So, as showed in two previous studies, in the se ing of PE-related pulmonary arterial hypertension with right heart dysfunction, hyponatremia may initiated the neurohormonal activation, and fi nally resulted in increased mortality of patients with PE. [11, 12] Chronic inflammation may lead to production of interleukin-6 at infl ammatory lesions, which can stimulate an excessive secretion of antidiuretic hormone resulting Simplifi ed PESI. Number in parenthesis indicates total number of patients in each groups. PESI = Pulmonary embolism severity index Figure 3 : Kaplan-Meier estimates of 30-day mortality by level of serum sodium in patients with pulmonary embolism without chronic heart failure, chronic obstructive pulmonary disease, chronic renal failure, and cancer, the cumulative mortality was 56.2, 25, and 18.8% for patients with a sodium level. <135, 135-137, and, ≥138 mmol/l (P < 0.002) in hypochloremia and hyponatremia. [5] Despite all these, recent hyponatremia treatment guidelines stated that "hyponatremia remains incompletely understood because of its association with a plethora of underlying disease states, and its multiple etiologies with diff ering pathophysiologic mechanisms." [13] Some studies about chronic heart failure show that correction of hyponatremia by use of vasopressin antagonists does not improve outcome in general, [5] but other studies had different consequences. [8, 14] Similar findings about pulmonary embolism are not available and prospective studies are necessary to determine whether correcting of hyponatremia improves outcomes or not.
Finally, more information is needed for using of serum sodium levels along with other known items of severity, in determining the prognosis of patients with pulmonary embolism.
Study limitations
1. Due to referrals role of our hospital, a measure of actual samples of selected patients may not accessible, and this may cause increase mortality of patients in this study compared to other studies. 2. In our patients, serum sodium levels a er discharge were not checked. So, the role of persistent hyponatremia vs. temporary hyponatremia cannot be evaluated. 3. In this study, the role of hyponatremia correction and modalities of PE treatment on prognosis are not assessed.
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